168 related articles for article (PubMed ID: 34459063)
1. FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression.
Tang Y; Jiang L; Zhao X; Hu D; Zhao G; Luo S; Du X; Tang W
Cell Biol Int; 2021 Dec; 45(12):2510-2520. PubMed ID: 34459063
[TBL] [Abstract][Full Text] [Related]
2. NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
Zhao X; Jiang L; Hu D; Tang Y; Zhao G; Du X; Luo S; Tang W
Exp Cell Res; 2021 Jun; 403(2):112614. PubMed ID: 33905671
[TBL] [Abstract][Full Text] [Related]
3. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
4. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
Chen X; Chen Z; Zheng B; Tang W
Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
[TBL] [Abstract][Full Text] [Related]
5. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
[TBL] [Abstract][Full Text] [Related]
6. FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
Shats I; Gatza ML; Liu B; Angus SP; You L; Nevins JR
Cancer Res; 2013 Oct; 73(19):6056-67. PubMed ID: 23966291
[TBL] [Abstract][Full Text] [Related]
7. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor HBP1 is a direct anti-cancer target of transcription factor FOXO1 in invasive oral cancer.
Chan CY; Huang SY; Sheu JJ; Roth MM; Chou IT; Lien CH; Lee MF; Huang CY
Oncotarget; 2017 Feb; 8(9):14537-14548. PubMed ID: 28099936
[TBL] [Abstract][Full Text] [Related]
9. LncRNA GAS5 Inhibits Cellular Proliferation by Targeting P27
Luo G; Liu D; Huang C; Wang M; Xiao X; Zeng F; Wang L; Jiang G
Mol Cancer Res; 2017 Jul; 15(7):789-799. PubMed ID: 28396462
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene.
Schayek H; Bentov I; Rotem I; Pasmanik-Chor M; Ginsberg D; Plymate SR; Werner H
Growth Horm IGF Res; 2010 Feb; 20(1):68-72. PubMed ID: 19703789
[TBL] [Abstract][Full Text] [Related]
11. MiR-1258 promotes the apoptosis of cervical cancer cells by regulating the E2F1/P53 signaling pathway.
Peng X; Zhang Y; Gao J; Cai C
Exp Mol Pathol; 2020 Jun; 114():104368. PubMed ID: 31917289
[TBL] [Abstract][Full Text] [Related]
12. Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer.
Yang N; Wu J; Zhang T; Yang F; Shao J; He C; Qin L
Comput Math Methods Med; 2021; 2021():8773423. PubMed ID: 34552661
[TBL] [Abstract][Full Text] [Related]
13. β-Arrestin2 Contributes to Cell Viability and Proliferation via the Down-Regulation of FOXO1 in Castration-Resistant Prostate Cancer.
Duan X; Kong Z; Liu Y; Zeng Z; Li S; Wu W; Ji W; Yang B; Zhao Z; Zeng G
J Cell Physiol; 2015 Oct; 230(10):2371-81. PubMed ID: 25752515
[TBL] [Abstract][Full Text] [Related]
14. A functional SNP in the MDM2 promoter mediates E2F1 affinity to modulate cyclin D1 expression in tumor cell proliferation.
Yang ZH; Zhou CL; Zhu H; Li JH; He CD
Asian Pac J Cancer Prev; 2014; 15(8):3817-23. PubMed ID: 24870800
[TBL] [Abstract][Full Text] [Related]
15. miR-5188 augments glioma growth, migration and invasion through an SP1-modulated FOXO1-PI3K/AKT-c-JUN-positive feedback circuit.
Yi R; Yang S; Lin X; Zhong L; Liao Y; Hu Z; Huang T; Long H; Lin J; Wu Z; Xie C; Ding S; Luo J; Luo Q; Song Y
J Cell Mol Med; 2020 Oct; 24(20):11800-11813. PubMed ID: 32902145
[TBL] [Abstract][Full Text] [Related]
16. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
17. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-629 promotes the tumorigenesis of non-small-cell lung cancer by targeting FOXO1 and activating PI3K/AKT pathway.
Zhu L; Chen Y; Liu J; Nie K; Xiao Y; Yu H
Cancer Biomark; 2020; 29(3):347-357. PubMed ID: 32716350
[TBL] [Abstract][Full Text] [Related]
19. Transcription Factor E2F1 Enhances Hepatocellular Carcinoma Cell Proliferation and Stemness by Activating GINS1.
Ren X; Shen L; Gao S
J Environ Pathol Toxicol Oncol; 2024; 43(1):79-90. PubMed ID: 37824372
[TBL] [Abstract][Full Text] [Related]
20. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
